Avalyn Pharma's IPO aims to fund inhaled IPF therapies as AP01 shows positive Phase II results. Read the full analysis here.

A new study has revealed the happiest locations in the United States — and the top spot may not be where you’d expect.

There seems to be a strong exposure-response relationship between nerandomilast and the preservation of FVC in patients with PPF and IPF.

Findings provide early evidence supporting potential disease-modifying activity of AP01 (inhaled pirfenidone) in patients with IPF BOSTON, March 25, 2026 (GLOBE NEWSWIRE)-- Avalyn Pharma Inc., ...

Sarah is an experienced writer and editor enthusiastic about helping readers live their healthiest and happiest lives. Before joining Forbes Health, Sarah worked as a writer for various digital ...

BOSTON, March 25, 2026 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc., (“Avalyn” or the “Company”), a clinical-stage biopharmaceutical company pioneering inhaled therapies to transform the treatment paradigm ...

David Novak and his late wife Wendy — who died from Type 1 diabetes complications in 2024 — spent their lives advocating for ...

India, March 30 -- E-cigarettes with nicotine may be the most effective tool for quitting smoking. They appear to outperform traditional nicotine replacement therapies such as patches, gum, and ...

Select your location to view local American Lung Association events and news near you.

MINNEAPOLIS — Research into the impact that prior antibiotics exposure may have on the risk for a new diagnosis of juvenile idiopathic arthritis (JIA) indicates that while antibiotics are associated ...